Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy

Kidney International

Volumn 58, Issue 3, 2000, Pages 1325-1335

  Foley, Robert N ^a,b,c,d   Parfrey, Patrick S ^a,b,c,d   Morgan, Janet ^a,b,c,d   Barre, Paul E ^a,b,c,d   Campbell, Pierre ^a,b,c,d   Cartier, P ^a,b,c,d   Coyle, Douglas ^a,b,c,d   Fine, Adrian ^a,b,c,d   Handa, Paul ^a,b,c,d   Kingman, Iris ^a,b,c,d   Lau, Cathy Y ^a,b,c,d   Levin, Adeera ^a,b,c,d   Mendelssohn, David ^a,b,c,d   Muirhead, Norman ^a,b,c,d   Murphy, Brendan ^a,b,c,d   Plante, Richard K ^a,b,c,d   Posen, Gerald ^a,b,c,d   Wells, George A ^a,b,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Chronic hemodynamic stress; End stage renal disease; Epoetin ; Ischemic heart disease; Progressive renal disease; Ventricular enlargement

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON DEXTRAN;

ADULT; ANEMIA; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0033857652     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00289.x     Document Type: Article

References (31)

1. Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine
2. Epidemiology of cardiovascular disease in chronic renal disease
3. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy
4. Impact of left ventricular hypertrophy on survival in end-stage renal disease
5. Outcome and risk factors for left ventricular disorders in chronic uraemia
6. The prognostic importance of left ventricular geometry in uremic cardiomyopathy
7. Long-term evolution of cardiomyopathy in dialysis patients
8. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
9. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
10. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
11. RHuEPO treatment improves brain and cognitive function of anemic dialysis patients
12. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin
13. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin
14. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin
15. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin
16. The effects of normal as compared with low hematocrit in patients with cardiac disease who are receiving hemodialysis and epoetin
17. Echocardiographic criteria for left ventricular hypertrophy. The Framingham Heart Study
18. A new classification of left ventricular geometry in patients with cardiac disease based on M-mode echocardiography
19. NKF-DOQI clinical practice guidelines for hemodialysis adequacy: National Kidney Foundation
20. The Committee on M-mode standardization of the American Society of Echocardiography: Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiographic measurements
21. Detection of left ventricular hypertrophy by M-mode echocardiography: Anatomic validation, standardization and comparison to other methods
22. Left ventricular volumes and ejection fraction by echocardiography
23. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis
24. The MOS 36-Item Short Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs
25. A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer
26. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease
27. Anemia in hemodialysis patients: Variables affecting this outcome predictor
28. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy Dialysis Registry
29. Hematocrit level and associated mortality in hemodialysis patents
30. Hemodilution reduces clinic and ambulatory blood pressure in polycythemic patients
31. Effects of epoetin on vascular biology